Canada: Theratechnologies Inc (Theratechnologies) (TSX:TH) announces that COFEPRIS, Mexico’s health agency, has approved the 1mg/vial presentation of tesamorelin for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy, allowing the commercialization of EGRIFTA® in this territory.
The approval of the 1mg/vial presentation comes in the footsteps of the 2mg/vial presentation approval which was received last July from Mexico’ s health agency.
“We are very excited by this news especially since it is the result of a long process. We have reached another important milestone towards our goal to offer EGRIFTA® to patients who are looking for a product addressing their condition. Our partner can now focus on the next steps in Mexico consisting in seeking reimbursement for the product and commercializing it,” said Luc Tanguay, President and CEO, Theratechnologies Inc.
EGRIFTA® was first approved by the United States Food and Drug Administration in November 2010 and by Health Canada in March 2015.